Esperion strikes Japan deal for 'goldilocks' cholesterol drug, bags $60M cash as pandemic forces virtual US rollout
Esperion has forged its first regional deal for Nexletol and Nexlizet since winning US and EU approvals for the cholesterol fighting drugs, bagging $60 million upfront while securing a pharma partner in Japan.
Not only is Otsuka promising $450 million in total milestones and 15% to 30% royalties, it’s also picking up the tab for all development, regulatory and sales in Japan — which Esperion estimates would amount to $100 million over the next few years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
